Clinic Roundup

• MicroDose Therapeutx Inc., of Monmouth Junction, N.J., completed its third and final Phase I study with its inhaled antiviral fusion inhibitor, MDT-637, for the treatment of respiratory syncytial virus. MicroDose presented the data from all three studies at the 8th Annual International Respiratory Syncytial Virus Symposium in Santa Fe, N.M.